investor.cyclacel.com
Investors & Media: Corporate Presentations & Events
http://investor.cyclacel.com/eventdetail.cfm?EventID=163763
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Corporate Presentations and Events. Corporate Presentations and Events. Second Quarter 2015 Financial Results. Aug 11, 2015. Back to previous page. Corporate Presentations and Events. Website created by Princeton Internet Group (PING).
investor.cyclacel.com
Investors & Media: RSS News Feeds
http://investor.cyclacel.com/rss.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Really Simple Syndication (RSS) is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates. How do I use RSS? Some web browsers, such as Firefox. To view a feed in your RSS Aggregator:. Form 4 SEC Filings.
scryingbiotech.com
Analysis – Scrying Biotech
http://scryingbiotech.com/category/analysis
These are my assessments, logical and of an occult nature, of biotechnology equities. Cyclacel Pharmaceuticals: What You Don’t Know. August 22, 2016. I am long (CYCC). I wrote this article myself and have not be compensated for it by any party mentioned or unknown. We are pleased to report that subsequent to the end of quarter the required number of events have been observed in the study approximately 1.7 years after the last patient was enrolled. Spiro Rombotis – August 10, 2016 – 4:30 PM ET. And the be...
investor.cyclacel.com
Investors & Media: Corporate Presentations & Events
http://investor.cyclacel.com/events.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Corporate Presentations and Events. Corporate Presentations and Events. Details on upcoming events are not yet available. August 2016 Corporate Presentation. Aug 12, 2016. Aug 10, 2016. Second Quarter 2016 Financial Results. May 11, 2016. First Quarter 2016 Financial Results. Mar 24, 2016. Fourth Quarter 2015 Financial Results.
investor.cyclacel.com
Investors & Media: Email Alert Subscription
http://investor.cyclacel.com/profile.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Step 1 of 3: Select Options. Quarterly and Annual Reports. All Events and Webcasts. In advance of any event. Send me a stock update at the end of the trading day. Alert me when the stock changes more than. Alert me when the stock crosses the following price thresholds:. Current Stock Price is $6.620.
investor.cyclacel.com
Investors & Media: SEC Filings
http://investor.cyclacel.com/sec.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Statement of beneficial ownership. Aug 19, 2016. Aug 11, 2016. Aug 10, 2016. Jul 6, 2016. Prospectus filed pursuant to rule 424. Jun 24, 2016. Jun 23, 2016. Prospectus filed pursuant to rule 424. Jun 10, 2016. Jun 3, 2016. Uprichard, david c. May 31, 2016. May 31, 2016. Hradsky, gregory t. May 31, 2016. Henney, christopher s.
investor.cyclacel.com
Investors & Media: Analysts
http://investor.cyclacel.com/analysts.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Michael G. King, Jr. Phone: 212 906 3520. Laidlaw and Company Ltd. Issued by the Board of Directors and Management of Cyclacel ("The Company"). Corporate Presentations and Events. Website created by Princeton Internet Group (PING).
tech.uchicago.edu
Start-Ups | UChicagoTech
http://tech.uchicago.edu/portfolio/startups
UChicagoTech - Center for Technology Development and Ventures. UChicago Researchers and Innovators. UChicago Researchers and Innovators. Report a New Discovery (Forms and Policies). Publicly Traded Companies Developed by UChicagoTech or ARCH Development. Companies Developed by UChicagoTech or ARCH Development. Acquired by Haemonetics) (HAE). Aviron (acquired by MedImmune. Acquired by McGraw-Hill) (MHP). Acquired by McGraw-Hill) (MHP). Hyseq (now part of Nuvelo now a part of Arca Biopharma.
investor.cyclacel.com
Investors & Media: Common Stock Information
http://investor.cyclacel.com/stockquote.cfm
Research and Development Pipeline. CYC116 Aurora Kinase and VEGFR2 Inhibitor. Cell Cycle in Cancer. Drug Discovery and Development Approach. Corporate Presentations and Events. Cyclacel Pharmaceuticals (NASDAQ: CYCC). 4:00 PM ET on Aug 22, 2016. Sign up for email alerts. Corporate Presentations and Events. Website created by Princeton Internet Group (PING).